Hospital
Multicare Health System
Multicare Health System was paid $55.23M by Medicaid between Jan 2018 and Dec 2024, across 429 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoMULTICARE HEALTH SYSTEM
SPOKANE, WA 99204
SPOKANE, WA 99204
33aNPI1356528269assigned 01/23/2008
33bProvider typeGeneral Acute Care Hospital
28Total paid$55.23M
24GClaims1,835,987
24DCodes billed429
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Washington
Rank by total paid#11 of 49
Median peer was paid$20.06M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ROBERTSON, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 221,965 | $6.38M | |
| 2019 | 251,126 | $7.59M | |
| 2020 | 244,297 | $7.59M | |
| 2021 | 295,373 | $8.70M | |
| 2022 | 290,091 | $9.11M | |
| 2023 | 279,275 | $8.10M | |
| 2024incomplete | 253,860 | $7.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 78,669 | 70,777 | $8.12M |
| 96361 | Intravenous infusion, hydration; each additional hour | 15% | 28,649 | 24,688 | $8.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.1% | 57,847 | 52,399 | $4.46M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 59,430 | 53,511 | $3.95M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.5% | 39,577 | 27,262 | $3.04M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 13,737 | 13,045 | $2.21M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.3% | 17,705 | 16,059 | $1.80M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.6% | 7,087 | 6,938 | $1.46M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 10,910 | 10,244 | $1.41M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 4,767 | 4,604 | $1.32M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 13,660 | 10,633 | $1.27M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.8% | 5,255 | 3,952 | $974K |
417 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 8,448 | $901K |
| 58661 | 1.5% | 348 | $838K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.5% | 2,370 | $837K |
| 29581 | 1.3% | 5,357 | $735K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.3% | 2,208 | $720K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 4,244 | $706K |
| 59025 | Fetal non-stress test | 1.2% | 4,868 | $684K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.0% | 2,016 | $573K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 18,100 | $568K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,710 | $541K |
| 95806 | <1% | 1,848 | $525K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 20,022 | $496K |
| 10060 | <1% | 1,933 | $330K | |
| 12001 | <1% | 1,802 | $324K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,999 | $305K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,277 | $294K |
| 93971 | <1% | 3,578 | $281K | |
| 97597 | <1% | 6,522 | $280K | |
| 80053 | Comprehensive metabolic panel | <1% | 78,183 | $279K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,519 | $271K |
| 93976 | <1% | 4,781 | $268K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,542 | $237K |
| 70496 | <1% | 1,728 | $230K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,659 | $220K |
| 96415 | <1% | 1,586 | $219K | |
| 93017 | <1% | 2,893 | $215K | |
| 50590 | <1% | 130 | $206K | |
| 93458 | <1% | 241 | $170K | |
| 96367 | <1% | 3,795 | $168K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12,426 | $157K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 301 | $153K |
| 43248 | <1% | 404 | $150K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,043 | $147K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 282 | $146K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 137 | $146K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,592 | $143K |
| 12002 | <1% | 849 | $137K | |
| 12011 | <1% | 722 | $131K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 63 | $106K |
| 93970 | <1% | 1,217 | $100K | |
| 70491 | <1% | 666 | $97K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12,462 | $92K |
| 84484 | <1% | 23,530 | $92K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 31,036 | $91K |
| 76801 | <1% | 2,368 | $89K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,145 | $81K |
| 17250 | <1% | 832 | $79K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,476 | $76K |
| 70486 | <1% | 2,595 | $75K | |
| 76937 | <1% | 2,300 | $71K | |
| G0378 | Hospital observation service, per hour | <1% | 9,874 | $68K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,088 | $61K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 8,885 | $60K |
| 52356 | <1% | 27 | $59K | |
| 29125 | <1% | 463 | $55K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,105 | $55K |
| 47562 | <1% | 27 | $54K | |
| 90715 | <1% | 3,108 | $53K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 38,004 | $51K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,410 | $48K |
| 74174 | <1% | 400 | $45K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 1,292 | $45K |
| 87505 | <1% | 716 | $44K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,518 | $44K |
| 95811 | <1% | 138 | $44K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,112 | $42K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,223 | $42K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 45,976 | $42K |
| 70498 | <1% | 1,731 | $40K | |
| 83605 | <1% | 8,612 | $39K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,423 | $38K |
| 87077 | <1% | 11,314 | $37K | |
| 76870 | <1% | 468 | $35K | |
| 87040 | <1% | 6,386 | $35K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 24,640 | $32K |
| 96416 | <1% | 121 | $31K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 210 | $31K |
| 93880 | <1% | 670 | $30K | |
| 64615 | <1% | 128 | $29K | |
| 83880 | <1% | 6,284 | $29K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 97 | $29K |
| 95813 | <1% | 106 | $28K | |
| 77386 | <1% | 122 | $28K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,491 | $26K |
| 80047 | <1% | 3,716 | $26K | |
| 93350 | <1% | 106 | $25K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 107 | $25K |
| 87254 | <1% | 1,646 | $24K | |
| 93325 | <1% | 553 | $22K | |
| 95819 | <1% | 157 | $21K | |
| J3490 | Unclassified drugs | <1% | 865 | $20K |
| 85379 | <1% | 5,449 | $20K | |
| 84145 | <1% | 2,463 | $20K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 544 | $19K |
| 96523 | <1% | 559 | $19K | |
| 87070 | <1% | 10,213 | $19K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,172 | $18K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,206 | $18K |
| 88307 | <1% | 1,067 | $18K | |
| 80050 | General health panel | <1% | 3,253 | $17K |
| 86850 | <1% | 6,501 | $17K | |
| 97598 | <1% | 1,085 | $17K | |
| 77334 | <1% | 226 | $16K | |
| 87400 | <1% | 1,539 | $14K | |
| 87186 | <1% | 8,079 | $14K | |
| 77336 | <1% | 306 | $14K | |
| 87184 | <1% | 5,196 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 19,065 | $13K |
| 74420 | <1% | 198 | $13K | |
| 76770 | <1% | 162 | $13K | |
| 86900 | <1% | 6,935 | $13K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,011 | $12K |
| A4649 | Surgical supply; miscellaneous | <1% | 7,186 | $12K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 339 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 35,098 | $11K |
| 76820 | <1% | 883 | $11K | |
| 87205 | <1% | 7,981 | $11K | |
| 77295 | <1% | 30 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,797 | $10K |
| 76818 | <1% | 894 | $10K | |
| 97162 | <1% | 309 | $10K | |
| 80179 | <1% | 2,401 | $9K | |
| 87209 | <1% | 1,318 | $8K | |
| 43235 | <1% | 28 | $8K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,569 | $8K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,151 | $8K |
| 36592 | <1% | 26,781 | $8K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 124 | $7K |
| 86901 | <1% | 7,303 | $7K | |
| 73630 | <1% | 3,571 | $7K | |
| 73130 | <1% | 3,304 | $6K | |
| 87088 | <1% | 6,446 | $6K | |
| 77300 | <1% | 161 | $6K | |
| 82947 | <1% | 9,510 | $6K | |
| 36430 | <1% | 96 | $6K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 88 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 25,452 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 41,204 | $6K |
| 85027 | <1% | 9,762 | $5K | |
| 87147 | <1% | 1,623 | $5K | |
| 87149 | <1% | 1,212 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 25,318 | $5K |
| 81003 | <1% | 42,461 | $5K | |
| 97165 | <1% | 173 | $5K | |
| 87045 | <1% | 1,004 | $5K | |
| 72131 | <1% | 375 | $5K | |
| 80143 | <1% | 2,485 | $5K | |
| 74018 | <1% | 1,913 | $5K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,856 | $5K |
| 87420 | <1% | 401 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,881 | $5K |
| 87177 | <1% | 1,334 | $5K | |
| 72100 | <1% | 1,956 | $4K | |
| 93308 | <1% | 29 | $4K | |
| 87081 | <1% | 2,116 | $4K | |
| 87634 | <1% | 187 | $4K | |
| 97161 | <1% | 157 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,063 | $4K |
| 83735 | <1% | 12,512 | $4K | |
| 84112 | <1% | 366 | $4K | |
| 81025 | <1% | 27,116 | $4K | |
| 84702 | <1% | 3,655 | $3K | |
| 95812 | <1% | 13 | $3K | |
| 87427 | <1% | 552 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 134 | $3K |
| 77002 | <1% | 25 | $3K | |
| 73610 | <1% | 3,594 | $3K | |
| 73560 | <1% | 2,687 | $3K | |
| 73502 | <1% | 1,820 | $3K | |
| 83690 | <1% | 17,270 | $3K | |
| 95816 | <1% | 17 | $3K | |
| 73030 | <1% | 3,059 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,436 | $3K |
| 64505 | <1% | 17 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,241 | $3K |
| 70487 | <1% | 16 | $3K | |
| 70552 | <1% | 12 | $2K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 21 | $2K |
| 81001 | <1% | 22,032 | $2K | |
| 76821 | <1% | 216 | $2K | |
| 73110 | <1% | 2,392 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15,185 | $2K |
| 82077 | <1% | 9,492 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,101 | $2K |
| 73700 | <1% | 39 | $2K | |
| 71250 | <1% | 57 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19,179 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 27,737 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 19,084 | $2K |
| 71101 | <1% | 1,294 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,478 | $2K |
| 87899 | <1% | 689 | $2K | |
| 36591 | <1% | 977 | $2K | |
| 96376 | <1% | 11,250 | $2K | |
| 99152 | <1% | 3,222 | $2K | |
| 96368 | <1% | 652 | $2K | |
| 93923 | <1% | 31 | $2K | |
| 87493 | <1% | 214 | $1K | |
| 85014 | <1% | 5,385 | $1K | |
| 85610 | <1% | 8,431 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 11,372 | $1K |
| 86140 | <1% | 3,230 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,594 | $1K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 12,517 | $1K |
| 73564 | <1% | 863 | $1K | |
| 87252 | <1% | 83 | $1K | |
| 20553 | <1% | 17 | $1K | |
| 73140 | <1% | 1,399 | $1K | |
| 77470 | <1% | 13 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 27,364 | $1K |
| 90714 | <1% | 76 | $1K | |
| 72040 | <1% | 386 | $1K | |
| 85730 | <1% | 5,262 | $1K | |
| 73090 | <1% | 903 | $1K | |
| 86923 | <1% | 95 | $1K | |
| 84703 | <1% | 5,825 | $1K | |
| 80061 | Lipid panel | <1% | 333 | $1K |
| 73080 | <1% | 840 | $1K | |
| 83630 | <1% | 85 | $987.49 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,110 | $930.82 |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,218 | $912.14 |
| 87430 | <1% | 4,389 | $904.78 | |
| 72128 | <1% | 107 | $837.00 | |
| 73590 | <1% | 1,177 | $833.87 | |
| 82553 | <1% | 247 | $777.26 | |
| 85018 | <1% | 1,022 | $776.70 | |
| 82731 | <1% | 58 | $766.35 | |
| 82550 | <1% | 2,120 | $760.19 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 92 | $744.99 |
| 90674 | <1% | 70 | $740.30 | |
| 87486 | <1% | 57 | $740.01 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 747 | $730.36 |
| 85007 | <1% | 4,549 | $728.08 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,498 | $716.97 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,932 | $701.49 |
| 93321 | <1% | 326 | $613.28 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 935 | $603.62 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,149 | $589.60 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,841 | $585.80 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 35 | $542.12 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 3,093 | $540.93 |
| 74022 | <1% | 272 | $539.32 | |
| 82565 | <1% | 1,391 | $538.70 | |
| 82962 | <1% | 1,117 | $535.59 | |
| 93922 | <1% | 12 | $520.66 | |
| 87075 | <1% | 499 | $516.62 | |
| 93798 | <1% | 41 | $502.64 | |
| 90686 | <1% | 55 | $494.50 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,597 | $493.03 |
| 87210 | <1% | 1,273 | $471.37 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 79 | $469.16 |
| 87046 | <1% | 83 | $460.45 | |
| 76376 | <1% | 303 | $453.24 | |
| 64400 | <1% | 18 | $449.15 | |
| 88342 | <1% | 1,519 | $436.27 | |
| 86780 | <1% | 202 | $429.30 | |
| 96417 | <1% | 1,037 | $425.57 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,700 | $419.79 |
| 80178 | <1% | 54 | $415.88 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,471 | $397.82 |
| 88304 | <1% | 1,695 | $397.48 | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 1,132 | $394.08 |
| 87641 | <1% | 80 | $391.73 | |
| C1769 | Guide wire | <1% | 4,130 | $391.38 |
| J1815 | Injection, insulin, per 5 units | <1% | 4,971 | $382.11 |
| 87581 | <1% | 57 | $370.05 | |
| G2215 | Take-home supply of nasal naloxone; 2-pack of 4mg per 0.1 ml nasal spray (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 37 | $369.54 |
| 36416 | <1% | 6,997 | $336.30 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 376 | $327.57 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,007 | $319.71 |
| 93797 | <1% | 46 | $296.16 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,688 | $292.21 |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 14 | $287.07 |
| 64405 | <1% | 17 | $287.06 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,580 | $278.89 |
| 87279 | <1% | 800 | $275.68 | |
| 80074 | <1% | 66 | $271.94 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,668 | $271.38 |
| 84132 | <1% | 1,976 | $257.24 | |
| 87300 | <1% | 1,043 | $246.15 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 59 | $236.77 |
| 87808 | <1% | 682 | $235.66 | |
| 84439 | <1% | 789 | $232.47 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 707 | $223.57 |
| 85652 | <1% | 1,690 | $215.67 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 327 | $202.37 |
| 87631 | <1% | 13 | $197.40 | |
| 82140 | <1% | 163 | $195.41 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,628 | $187.82 |
| 84100 | <1% | 518 | $186.02 | |
| 51798 | <1% | 196 | $180.24 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,173 | $179.57 |
| 85046 | <1% | 56 | $176.57 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,572 | $174.60 |
| C1781 | Mesh (implantable) | <1% | 288 | $172.08 |
| 73660 | <1% | 83 | $163.32 | |
| 82803 | <1% | 1,856 | $160.79 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 168 | $157.80 |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 215 | $156.92 |
| C9399 | Unclassified drugs or biologicals | <1% | 109 | $155.19 |
| 87253 | <1% | 13 | $152.93 | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 247 | $152.78 |
| 72170 | <1% | 99 | $151.19 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 419 | $147.14 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,087 | $145.09 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 930 | $143.93 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,189 | $143.45 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 350 | $140.35 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,436 | $138.10 |
| 80305 | <1% | 327 | $137.74 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,436 | $121.93 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 307 | $117.56 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,090 | $107.42 |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 354 | $106.47 |
| 96411 | <1% | 296 | $100.12 | |
| 87280 | <1% | 377 | $93.48 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 5,104 | $80.33 |
| 86141 | <1% | 12 | $79.92 | |
| 72070 | <1% | 146 | $79.52 | |
| 85651 | <1% | 302 | $67.99 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 97 | $64.69 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 16 | $63.57 |
| 86762 | <1% | 19 | $61.47 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 113 | $61.03 |
| 82009 | <1% | 510 | $60.47 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 454 | $59.54 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,252 | $46.53 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 38 | $45.98 |
| 84550 | <1% | 227 | $43.75 | |
| 73000 | <1% | 13 | $43.48 | |
| 73060 | <1% | 81 | $41.72 | |
| C1758 | Catheter, ureteral | <1% | 704 | $41.49 |
| 88302 | <1% | 304 | $38.06 | |
| 82010 | <1% | 232 | $36.31 | |
| 87206 | <1% | 19 | $36.26 | |
| 82570 | <1% | 91 | $33.74 | |
| 84156 | <1% | 91 | $31.28 | |
| 87260 | <1% | 29 | $26.36 | |
| 87101 | <1% | 14 | $25.85 | |
| 87807 | <1% | 196 | $24.04 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,241 | $15.72 |
| C1729 | Catheter, drainage | <1% | 155 | $15.00 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,470 | $14.81 |
| 88341 | <1% | 41 | $10.80 | |
| 83615 | <1% | 15 | $10.43 | |
| 81000 | <1% | 165 | $9.07 | |
| 82800 | <1% | 239 | $7.73 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 73 | $6.90 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 165 | $2.99 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 260 | $2.90 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 22 | $2.16 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 707 | $1.43 |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 2,142 | $1.33 |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | <1% | 49 | $1.04 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,139 | $0.73 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 13,628 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 303 | $0.00 |
| 0042T | 0% | 425 | $0.00 | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 502 | $0.00 |
| 85347 | 0% | 72 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 286 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 617 | $0.00 |
| 80076 | 0% | 53 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 425 | $0.00 |
| J2359 | Injection, olanzapine, 0.5 mg | 0% | 31 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 77 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 28 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 39 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 305 | $0.00 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 14 | $0.00 |
| 73562 | 0% | 13 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 62 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 80 | $0.00 |
| 0225U | 0% | 27 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 99 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 341 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 74 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 84 | $0.00 |
| 93356 | 0% | 26 | $0.00 | |
| 82272 | 0% | 46 | $0.00 | |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 67 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 83 | $0.00 |
| 83540 | 0% | 12 | $0.00 | |
| 73070 | 0% | 14 | $0.00 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 16 | $0.00 |
| 85049 | 0% | 26 | $0.00 | |
| A4358 | Urinary drainage bag, leg or abdomen, vinyl, with or without tube, with straps, each | 0% | 13 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 338 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 60 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 460 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 111 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 719 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 617 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 70 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 46 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 26 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 132 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 135 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 28 | $0.00 |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | 0% | 79 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 189 | $0.00 |
| A9270 | Non-covered item or service | 0% | 540 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 25 | $0.00 |
| 74019 | 0% | 24 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 42 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 58 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 40 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 83 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 644 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 92 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 55 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 56 | $0.00 |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | 0% | 12 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 27 | $0.00 |
| C1747 | Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable) | 0% | 15 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROBERTSON, WILLIAM (CEO)
| Provider | Location | Paid |
|---|---|---|
| Multicare Health System | Tacoma, WA | $162.25M |
| Multicare Health System | Tacoma, WA | $108.54M |
| Yakima Valley Memorial Hospital Association | Yakima, WA | $103.54M |
| Multicare Health System | Puyallup, WA | $77.99M |
| Multicare Health System | Tacoma, WA | $75.17M |
| Greater Lakes Mental Health Foundation INC | Lakewood, WA | $55.95M |
| Multicare Health System | Auburn, WA | $31.02M |
| Multicare Health System | Spokane Valley, WA | $24.75M |
| Multicare Health System | Covington, WA | $23.19M |
| Multicare Health System | Olympia, WA | $16.97M |
| Multicare Health System | Tacoma, WA | $11.14M |
| Multicare Health System | Auburn, WA | $7.42M |
| Multicare Health System | Tacoma, WA | $2.68M |
| Alliance for South Sound Health | Tacoma, WA | $2.46M |
| Capital Medical Center Physicians LLC | Olympia, WA | $1.75M |
| Multicare Health System | Tacoma, WA | $1.53M |
| Yakima Valley Memorial Hospital Association | Yakima, WA | $1.16M |
| Capital Medical Center Specialty Physicians, LLC | Olympia, WA | $987K |
| Yakima Urology at Memorial TR | Yakima, WA | $784K |
| Multicare Health System | Spokane, WA | $179K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.